5-Imino-1,2,4-Thiadiazoles: First Small Molecules As Substrate Competitive Inhibitors of Glycogen Synthase Kinase 3
Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Nuria E. Campillo(Centro de Investigaciones Biológicas Margarita Salas), Arantxa Encinas(Instituto de Química Médica), José Á. Morales-García(Universitat de Vic - Universitat Central de Catalunya), Ana Pérez‐Castillo(Instituto de Investigaciones Biomédicas Sols-Morreale), Carmen Gil(Instituto de Salud Carlos III), Ana Castro(Instituto de Química Médica), Ignacio Soteras(Instituto de Química Médica), Sandra Alonso‐Gil(Biomedical Research Networking Center on Neurodegenerative Diseases), Daniel I. Pérez(Cedars-Sinai Medical Center), Concepción Pérez(Instituto de Química Médica)
Cited by 92
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293